Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human chorionic gonadotropin superagonist
- Development stage
- Preclinical
- Lead developer
- Trophogen
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
The human chorionic gonadotropin (hCG) superagonist is a recombinant, long-acting, high-potency modified glycoprotein hormone developed by Trophogen. It is designed using Trophogen's proprietary platform technology, which involves introducing amino acid substitutions (such as basic residues in the alpha subunit) to enhance electrostatic interactions with the luteinizing hormone/choriogonadotropin receptor (LHCGR). This results in significantly increased receptor binding affinity and bioactivity compared to wild-type hCG. The drug is being developed as a therapeutic agent for the treatment of female infertility, supporting ovulation and other assisted reproductive technology (ART) processes. It is currently in preclinical development.
- Other names
- hCG superagonisthuman LH/CG superagonisthuman LH superagonistrecombinant human chorionic gonadotropin superagonistrecombinant human LH/CG superagonist
02
Targets
FSHR (Follicle-stimulating hormone receptor)MRC1 (Mannose Receptor C-type 1)TSHR (Thyroid-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on human chorionic gonadotropin superagonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human chorionic gonadotropin superagonist.